Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 17, 2020 (6 years ago)

labetalol HCl 20 mg/4 mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

labetalol HCl 20 mg/4 mL, Injection for Intravenous Use (5mg/mL), Rx Only, 4 mL Single Dose Syringe, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT, 06095, barcode 70004070028

Drug: Labetalol

Recalling firm
SCA Pharmaceuticals
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0198-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Labetalol recalls

See all
Class II · Moderate risk

PF-Labetalol HCl Injection

CGMP Deviations: Potential for cross contamination due to product carry over.

Terminated Cross-contamination Nephron Sterile Compounding Center LLC NDC 69374-946-34 D-0064-2023
Class II · Moderate risk

PF-Labetalol HCl Injection

CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.

Terminated Cross-contamination Nephron Sterile Compounding Center LLC NDC 69374-946-34 D-1347-2022

Other recalls by SCA Pharmaceuticals

All 2020 recalls